GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Celadon Pharmaceuticals PLC (LSE:CEL) » Definitions » Total Assets

Celadon Pharmaceuticals (LSE:CEL) Total Assets : €10.70 Mil (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Celadon Pharmaceuticals Total Assets?

Celadon Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2023 was €10.70 Mil.

During the past 12 months, Celadon Pharmaceuticals's average Total Assets Growth Rate was -1.90% per year. During the past 3 years, the average Total Assets Growth Rate was 33.00% per year.

During the past 5 years, Celadon Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 47.50%. The lowest was 33.00%. And the median was 40.25%.

Total Assets is connected with ROA %. Celadon Pharmaceuticals's annualized ROA % for the quarter that ended in Dec. 2023 was -60.66%. Total Assets is also linked to Revenue through Asset Turnover. Celadon Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2023 was 0.01.

Celadon Pharmaceuticals Total Assets Historical Data

The historical data trend for Celadon Pharmaceuticals's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celadon Pharmaceuticals Total Assets Chart

Celadon Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Total Assets
2.94 4.26 - 15.24 10.70

Celadon Pharmaceuticals Semi-Annual Data
Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Assets Get a 7-Day Free Trial 7.78 19.15 15.24 11.03 10.70

Celadon Pharmaceuticals Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Celadon Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets=Total Equity (A: Dec. 2023 )+Total Liabilities (A: Dec. 2023 )
=3.692+7.011
=10.70

Celadon Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2023 is calculated as

Total Assets=Total Equity (Q: Dec. 2023 )+Total Liabilities (Q: Dec. 2023 )
=3.692+7.011
=10.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celadon Pharmaceuticals  (LSE:CEL) Total Assets Explanation

Total Assets is connected with ROA %.

Celadon Pharmaceuticals's annualized ROA % for the quarter that ended in Dec. 2023 is

ROA %=Net Income (Q: Dec. 2023 )/( (Total Assets (Q: Jun. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=-6.59/( (11.025+10.703)/ 2 )
=-6.59/10.864
=-60.66 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Celadon Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2023 is

Asset Turnover
=Revenue (Q: Dec. 2023 )/( (Total Assets (Q: Jun. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=0.078/( (11.025+10.703)/ 2 )
=0.078/10.864
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Celadon Pharmaceuticals Total Assets Related Terms

Thank you for viewing the detailed overview of Celadon Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Celadon Pharmaceuticals (LSE:CEL) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Celadon Pharmaceuticals PLC (LSE:CEL) » Definitions » Total Assets
Comparable Companies
LSE:STX LSE:AGY LSE:EAH LSE:VLG LSE:CHLL LSE:PXS LSE:ANCR AQSE:ANA LSE:HELD LSE:N4P ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
N/A
Address
32-33 Cowcross Street, London, GBR, EC1M 6DF
Website
https://www.celadonpharma.co.uk
Celadon Pharmaceuticals PLC focuses on growing indoor hydroponic high-quality cannabis initially for use within the chronic pain market. It has two reportable segments Celadon is a Build of grow facilities, growing medical grade cannabis and research in the GMP lab, and Harley Street (CPC) is a clinical study into the pain relief benefits of medicinal cannabis.

Celadon Pharmaceuticals (LSE:CEL) Headlines

No Headlines